Gyre Therapeutics Inc
GYRE7.020USD
+0.370+5.56%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
615.21MValor de mercado
84.84P/L TTM
Mais detalhes de Gyre Therapeutics Inc Empresa
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.
Informações da empresa
Código da empresaGYRE
Nome da EmpresaGyre Therapeutics Inc
Data de listagemApr 12, 2006
CEODr. Han Ying, Ph.D.
Número de funcionários574
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 12
Endereço12770 High Bluff Drive, Suite 150
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92130
Telefone16199493681
Sitehttps://www.gyretx.com/
Código da empresaGYRE
Data de listagemApr 12, 2006
CEODr. Han Ying, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.84M
-3.64%
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
+7.69%
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Han Ying, Ph.D.
Dr. Han Ying, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Mr. Ping Zhang
Mr. Ping Zhang
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Gordon G. Carmichael, Ph.D.
Mr. Gordon G. Carmichael, Ph.D.
Independent Director
Independent Director
--
--
Dr. Renate Parry, Ph.D.
Dr. Renate Parry, Ph.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.84M
-3.64%
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
+7.69%
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Han Ying, Ph.D.
Dr. Han Ying, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
GNI Group Ltd
82.60%
Luo (Ying)
3.22%
Ma (Songjiang)
3.22%
The Vanguard Group, Inc.
1.24%
Ye (Weiguo)
0.79%
Other
8.92%
Investidores
Investidores
Proporção
GNI Group Ltd
82.60%
Luo (Ying)
3.22%
Ma (Songjiang)
3.22%
The Vanguard Group, Inc.
1.24%
Ye (Weiguo)
0.79%
Other
8.92%
Tipos de investidores
Investidores
Proporção
Corporation
82.60%
Individual Investor
7.26%
Investment Advisor
2.11%
Investment Advisor/Hedge Fund
0.69%
Research Firm
0.19%
Hedge Fund
0.02%
Other
7.14%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
123
81.82M
92.88%
+8.77M
2025Q1
126
82.96M
94.19%
+9.94M
2024Q4
117
71.62M
76.58%
-277.10K
2024Q3
117
71.44M
76.41%
-69.01K
2024Q2
108
71.18M
81.40%
+2.80M
2024Q1
95
70.73M
80.87%
+2.43M
2023Q4
101
67.57M
93.09%
+2.43M
2023Q3
124
846.01K
34.20%
-1.22M
2023Q2
137
853.88K
34.77%
-909.13K
2023Q1
173
927.40K
37.69%
-976.07K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
GNI Group Ltd
72.77M
82.6%
+8.77M
+13.70%
Mar 12, 2025
Luo (Ying)
2.84M
3.22%
--
--
Sep 06, 2024
Ma (Songjiang)
2.84M
3.22%
-107.21K
-3.64%
Mar 12, 2025
The Vanguard Group, Inc.
1.10M
1.24%
+774.02K
+240.03%
Mar 31, 2025
Ye (Weiguo)
700.00K
0.79%
+50.00K
+7.69%
Apr 01, 2025
BlackRock Institutional Trust Company, N.A.
506.93K
0.58%
+12.53K
+2.53%
Mar 31, 2025
Geode Capital Management, L.L.C.
312.32K
0.35%
+8.22K
+2.70%
Mar 31, 2025
State Street Global Advisors (US)
128.77K
0.15%
+2.13K
+1.68%
Mar 31, 2025
SBI Securities Co., Ltd.
123.63K
0.14%
+22.39K
+22.12%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
111.42K
0.13%
-3.15K
-2.75%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Russell 2000 Growth ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Small-Cap ETF
0%
iShares Morningstar Small-Cap Value ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
iShares Russell 2000 Value ETF
0%
Ver Mais
iShares Russell 2000 Growth ETF
Proporção0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
Schwab U.S. Small-Cap ETF
Proporção0%
iShares Morningstar Small-Cap Value ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Data
Tipo
Proporção
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
